Teladoc Faces Pressure Over Capital Allocation And Stock Underperformance (UPDATED)

Editor's Note: This article has been updated to include a statement from a Teladoc Health spokesperson. Pineal Capital Management has called on the board of Teladoc Health Inc. (NYSE:TDOC) to take urgent steps to unlock shareholder value, warning that the company's depressed valuation leaves it exposed to a potential opportunistic takeover. The investment advisor, which holds a stake in Teladoc through Pineal Capital Fund 1, said it has engaged with management for months but remains concerned about the board's slow pace of action on critical strategic issues. Pineal argues that Teladoc's current market price significantly undervalues its long-term growth prospects, despite its leadership position in virtual healthcare and a member base exceeding 100 million users globally. Benzinga reached out to Teladoc Health for comment on the Pineal Capital letter. A spokesperson for the company responded, stating: "We value ongoing, constructive dialogue with our shareholders and are always open to hearing their perspectives. We have been engaging with Pineal and will continue doing so, and we appreciate their input and interest. We remain focused on executing our strategy, serving our customers, and driving performance that creates long-term value." Concerns Over Capital Allocation And Governance The firm highlighted a series of missteps that have weighed on investor confidence, including past acquisitions and capital allocation decisions. It specifically pointed to the 2020 Livongo acquisition, which it described as overvalued and poorly timed, questioning the decision to partially fund the deal with debt despite a strong equity valuation at the time. More recent deals—including Catapult, UpLift, and Telecare Australia—were also scrutinized, with Pineal noting a lack of clarity on their financial contribution and highlighting goodwill impairments tied to some transactions. The investor further criticized the absence of share buybacks, arguing that Teladoc has failed to act despite a significantly undervalued stock and an under-levered balance sheet. Teladoc Stock Performance And Communication Gaps Teladoc shares have declined more than 90% from pre-COVID highs, even as the company strengthened its competitive positioning. Pineal said the lack of a clearly articulated multi-year strategy, including limited investor communication and no recent Investor Day, has added to market uncertainty. The firm also flagged ongoing equity dilution from stock-based compensation, noting that shares outstanding have nearly doubled since 2020 without offsetting buybacks. Proposed Value-Unlock Strategy Pineal outlined a three-part plan to improve performance, including cost reductions, a $200 million-plus share repurchase program, and a full strategic review. The review could include separating Teladoc's Integrated Care and BetterHelp segments, which Pineal believes would eliminate a "conglomerate discount" and unlock value. Growth Tailwinds And Hidden Asset Value Despite its criticisms, Pineal emphasized strong underlying fundamentals, including favorable policy changes, the rollout of a 24/7 virtual care platform, and growth in BetterHelp's insurance-based model. The firm also identified Teladoc's mental health segment as a "hidden crown jewel," citing over $1.1 billion in related revenue in 2025 and significant long-term growth potential. It added that recent valuation multiples in comparable transactions, such as Talkspace, further highlight the disconnect between Teladoc's current valuation and its intrinsic worth. TDOC Reported Stronger-Than-Expected Quarterly Results In February, Teladoc Health reported a quarterly loss of 14 cents per share, which was better than the consensus loss of 18 cents. Additionally, sales increased to $642.27 million, surpassing the expected $635.24 million, driven by a 24% rise in other revenue streams, although access fees revenue fell by 4%. Teladoc Health expects the first quarter 2026 loss to be between 35-45 cents compared to the consensus loss of 25 cents, with sales of $598-$620 million versus the consensus of $633.75 million. The telehealth company sees a fiscal 2026 loss of 70 cents to $1.10, with sales of $2.47 billion to $2.59 billion, compared to the consensus of 76 cents and $2.55 billion, respectively. TDOC Stock Price Activity: Teladoc Health shares were down 0.64% at $5.52 at the time of publication on Wednesday, according to Benzinga Pro data. Image via Teladoc